IM
RPRX icon

Islet Management’s Royalty Pharma RPRX Stock Holding History

Islet Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-150,000
Closed -$7.28M – 152
2020
Q2 		$7.28M Buy
+150,000
New +$7.42M 0.83% 42

Other funds holding RPRX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RWJF
Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Islet Management's RPRX Position: Q3 2020 in Review

Islet Management sold out of Royalty Pharma (RPRX) in Q3 2020, closing a stake of 150,000 shares — an estimated $7.28M sold.

Islet Management first reported a position in RPRX in Q2 2020 and held it in 1 quarter. The position peaked at $7.28M in Q2 2020. 134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

  • Islet Management reported no remaining Royalty Pharma position as of Q3 2020 after selling out during the quarter.
  • Islet Management sold 150,000 Royalty Pharma shares in Q3 2020, an estimated $7.28M.
  • Islet Management first reported a position in Royalty Pharma in Q2 2020 and held it in 1 quarter.
  • Islet Management's Royalty Pharma position peaked at $7.28M in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on Islet Management's 13F filing for Q3 2020, filed 16 Nov 2020.